reference/27761595

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27761595

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Randomized Controlled Trial\|Research Support, U.S. Gov't, Non-P.H.S.
endingPage	466
issn	1473-3099
issueIdentifier	4
pageRange	455-466
publicationName	The Lancet. Infectious diseases
startingPage	455
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_8a84060532d8b9418fd17a2962a3d068
bibliographicCitation	Clarke DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi CS, Luckay A, Witko SE, Hermida L, Higgins T, Tremblay M, Sciotto-Brown S, Chen T, Egan MA, Rusnak JM, Ward LA, Eldridge JH. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Apr;20(4):455–66. doi: 10.1016/s1473-3099(19)30614-0. PMID: 31952923.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c7e74277e630c3f36f5641c2370e19e2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0cb4da86e0591ebe5505584c3d77520e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d750883b5b904c0e2def108212a8dad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8dd3c94ce5d7cc034084de4633ad702b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28550e43009605f648dbc8d8d20d72d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_11c6ed2e68cb5d60dde4141f01ddb695 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa18ea53f6f78049c1c13ae159dc46a3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b510ab18c4c96cd91bc0f071356d4acb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_80155e15a4e9e28a678bf49cdb317763 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4e562f3411e8b470c11616801de8b23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20a32a5b4a41ae78aa70c77a1a845c93 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2be4606248b39ba622987fcc5b8f6a5d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e695bd27c16ca27af9f7ef34a3fa8615 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d8f7f3a71405d4c494f2461de71d6fd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b58b952a186f4e1134bb2caf5be229ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a63ad28efa15344efaa3e05898b60946 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f44be359eeccd34d343a4ebf1f8d9354
date	202004
identifier	https://doi.org/10.1016/s1473-3099%2819%2930614-0 https://pubmed.ncbi.nlm.nih.gov/31952923
isPartOf	https://portal.issn.org/resource/ISSN/1473-3099 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27022
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial
discusses	http://id.nlm.nih.gov/mesh/M0022454 http://id.nlm.nih.gov/mesh/M0452769 http://id.nlm.nih.gov/mesh/M0009493
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D012449 http://id.nlm.nih.gov/mesh/D000071497 http://id.nlm.nih.gov/mesh/D019142Q000517 http://id.nlm.nih.gov/mesh/D046129Q000276 http://id.nlm.nih.gov/mesh/D029043Q000276 http://id.nlm.nih.gov/mesh/D006023Q000276
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D046129Q000008 http://id.nlm.nih.gov/mesh/D014613Q000276 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D014611 http://id.nlm.nih.gov/mesh/D064368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6965 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8015 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10345 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9034 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8937 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10294

Showing number of triples: 1 to 64 of 64.